Fosravuconazole is under clinical development by Eisai and currently in Phase III for Fungal Infections. According to GlobalData, Phase III drugs for Fungal Infections have a 53% phase transition ...
Allergic bronchopulmonary aspergillosis is a pulmonary disease occurring in patients with asthma or cystic fibrosis, consequent to a dysregulated immune response to inhaled Aspergillus conidia.